Akademik Veri Yönetim Sistemi
JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.3, ss.596-602, 1995 (SCI-Expanded)
Purpose: To evaluate a high-dose chemotherapy regimen without total-body irradiation (TBI) followed by allogeneic (allo) bone marrow transplantation (BMT) in patients with lymphoid malignancies who had received prior dose-limiting radiotherapy. Patients and Methods: Fifty-six patients with non-Hodgkin's lymphoma (NHL, n = 26), Hodgkin's disease (HD, n = 17), or acute lymphoblastic leukemia (ALL, n = 13) with a history of previous radiation therapy were treated with cyclophosphamide (7.2 g/m(2)), carmustine (300 mg/m(2) or 600 mg/m(2)), and etoposide (2,400 mg/ m(2); CBV) followed by allo BMT. Results: Nine of 56 patients are alive and disease-free a median of 1,091 (range, 512 to 1,784) days posttransplant. The probabilities of transplant-related mortality, relapse, and event-free survival at 2 years for the entire group of 56 patients were .62, .59, and .17, respectively. Patients who received 600 mg/m(2) of carmustine had a higher incidence of grade 3 or 4 regimen-related toxicities (RRTs) (14 of 22) than did patients who received 300 mg/m(2) (12 of 33; P < .04), whereas there was no difference in relapse (.34 and .53, respectively, P = .73). Fourteen of 16 patients who received allo BMT for advanced disease (n = 12) or less-advanced disease (n = 4) but who were also eligible for auto BMT relapsed (n = 4) or died of transplant-related complications (n = 10). Conclusion: Allo BMT following a high-dose CBV regimen resulted in long-term disease-free survival in 17% of patients with lymphoid malignancies who had received prior dose-limiting radiotherapy. A high incidence of transplant-related complications, especially fatal idio pathic pneumonia syndrome (IFS) and a high relapse rate limited success. Morbidity and mortality associated with carmustine 600 mg/m(2) were high and were not associated with a decrease in relapse. The number of patients in this study eligible for either allo or auto BMT was limited and precluded meaningful analysis of relative effectiveness. (C) 1995 by American Society of Clinical Oncology.